Michael Foeth
Head of Industrials in the Vontobel Research Team
Find out first-hand what vaccines pharmaceutical companies currently have in their pipeline and how they work. In addition, are global supply chains ready to handle vaccine distribution efficiently? Where are bottlenecks to be expected? What sectors are involved in mastering this Herculean logistical task?
In the video: Presentation and background information on the latest study “Corona vaccines and logistics”. Our analysts from the Swiss Research Team present their results and summarize the current situation from an investor’s point of view. © Vontobel, recorded on January 20, 2020, 1:00 p.m.
Head of Industrials in the Vontobel Research Team
Michael Foeth is Head of Swiss Industrial Research at Vontobel. He joined Vontobel in 2006 as a financial analyst specializing on technology, business services and logistics, and was involved in numerous IPOs in those sectors. Previously, he spent six years with Lombard Odier & Cie, responsible for the coverage of technology and logistics companies. Michael Foeth lectured science and technology at the University of Geneva between 1999 and 2005. He holds PhD in Physics from the ETH Lausanne (EPFL), a masters degree in Physics from the University of Geneva, and is a CFA charterholder.
Head of Life Sciences at Vontobel Research, molecular biologist and Chartered Financial Analyst (CFA)
Stefan Schneider joined Vontobel in February 2015 as Head of Life Sciences. Prior to that, he worked for ten years for the CIO WM Research Team at UBS, where he headed the European Equity Research and Equity Healthcare Research teams. Before his career in the financial sector, Mr. Schneider held senior positions at Roche.
Stefan Schneider holds a Ph.D. from the Institute of Medical Virology at University Zurich and is a CFA charterholder.
Head of Swiss Equity Research
Peter Romanzina joined Vontobel as Head of Brokerage in September 2010. He began his career at various banks in portfolio and asset management in Geneva, London, and Zurich before joining Schweizerische Kreditanstalt (SKA) in 1995. At SKA and later for Credit Suisse/First Boston (CSFB), he began as a research salesman for Swiss equities in Zurich and London. From 1998 to 2000, he headed Swiss Equity Research for CSFB and was also responsible for the Swiss equity strategy. From 2001 to 2010, he headed the brokerage business in Switzerland for Kepler (formerly Julius Baer) and was a member of the European Management Board.
Peter Romanzina is chartered financial analyst (CFA), financial risk manager (FRM), certified financial analyst and portfolio manager (CIIA).